R
Rob L. H. Jansen
Researcher at Maastricht University
Publications - 51
Citations - 4070
Rob L. H. Jansen is an academic researcher from Maastricht University. The author has contributed to research in topics: Cancer & Prospective cohort study. The author has an hindex of 23, co-authored 46 publications receiving 3390 citations.
Papers
More filters
Journal ArticleDOI
Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal Cancer
Monique Maas,Regina G. H. Beets-Tan,Doenja M. J. Lambregts,Guido Lammering,Patty J. Nelemans,Sanne M. E. Engelen,Ronald M. van Dam,Rob L. H. Jansen,Meindert N. Sosef,Jeroen W. A. Leijtens,Karel W.E. Hulsewé,Jeroen Buijsen,Geerard L. Beets +12 more
TL;DR: A wait-and-see policy with strict selection criteria, up-to-date imaging techniques, and follow-up is feasible and results in promising outcome at least as good as that of patients with a pCR after surgery.
Journal ArticleDOI
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Walter Taal,HM Oosterkamp,Annemiek M E Walenkamp,Hendrikus J. Dubbink,Laurens V. Beerepoot,Monique Hanse,Jan Buter,Aafke H. Honkoop,Dolf Boerman,Filip de Vos,Winand N.M. Dinjens,Roelien H. Enting,Martin J B Taphoorn,Franchette W P J van den Berkmortel,Rob L. H. Jansen,Dieta Brandsma,Jacoline E C Bromberg,Irene van Heuvel,René M. Vernhout,Bronno van der Holt,Martin J. van den Bent +20 more
TL;DR: The first randomised controlled phase 2 trial of bevacizumab in recurrent glioblastoma reported overall survival at 9 months, and the combined treatment was well tolerated.
Journal ArticleDOI
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H.J. Simkens,Harm van Tinteren,Anne May,Albert J. ten Tije,Geert-Jan Creemers,Olaf Loosveld,Felix E de Jongh,Frans L. G. Erdkamp,Zoran Erjavec,Adelheid M. E. van der Torren,Jolien Tol,Hans J Braun,Peter Nieboer,Jacobus J.M. van der Hoeven,Janny G. Haasjes,Rob L. H. Jansen,Jaap Wals,Annemieke Cats,Veerle A. Derleyn,Aafk E. H. Honkoop,Linda Mol,Cornelis J. A. Punt,Miriam Koopman +22 more
TL;DR: Maintenance treatment with capecitabine plus bevacizumab after six cycles of CAPOX-B in patients with metastatic colorectal cancer is effective and does not compromise quality of life.
Journal ArticleDOI
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
Annemieke Cats,Edwin P.M. Jansen,Nicole C.T. van Grieken,Karolina Sikorska,Pehr Lind,Marianne Nordsmark,Elma Meershoek-Klein Kranenbarg,Henk Boot,Anouk K. Trip,HA A. Maurits Swellengrebel,Hanneke W. M. van Laarhoven,Hein Putter,Johanna W. van Sandick,Mark I. van Berge Henegouwen,Henk H. Hartgrink,Harm van Tinteren,Cornelis J.H. van de Velde,Marcel Verheij,Frits van Coevorden,Steven Vanhoutvin,Maarten C.C.M. Hulshof,Olaf Jl Loosveld,A (Bert) Jan Ten Tije,Frans L. G. Erdkamp,Fabiënne A. R. M. Warmerdam,Donald L. van der Peet,Henk M.W. Verheul,Djamila Boerma,Maartje Los,Annerie Slot,Danny Houtsma,Johanna E.A. Portielje,Reinoud J. B. Blaisse,Ernst Jan Spillenaar Bilgen,Marco B Polée,Maud M. Geenen,Jeffrey P.B.M. Braak,Karen J. Neelis,Marije Slingerland,Rob L. H. Jansen,Jeroen Buijsen,Aart Beeker,Quirijn A. J. Eijsbouts,Johanna Mgh Van Riel,Tom Rozema,Dick Johan van Spronsen,Jetske M. Meerum Terwogt,Bea C Tanis,Adelheid Me Van der Torren-Conze,Richard Van Hilligersberg,Miriam Koopman,Marien O Den Boer,Geert-Jan Creemers,Maurice J.C. van der Sangen,Marjolein Em Rentinck,H Pieter van den Berg,Ge Jpm Jonkers,Diane Grootenboers,Annelie Je Vulink,Sjoerd Hovenga,Huub van der Mijle,Arnold Baars,A. Haringhuizen,Marije Ie Appels,Ron C Rietbroek,Ellen M Hendriksen,Marie-Cecile Jc Legdeur,Daan Ten Bokkel Huinink,O Aart Van Dobbenburgh,Jitty M Smit,Aart Van Bochove,Gerrit-Jan Veldhuis,Erik W Muller,Johannes J. Bonenkamp,Pètra M Braam,Jaap De Boer,Henk K Van Halteren,Fransje Aa Valster,Alex L. T. Imholz,Marjan A Van Dijk,Ate van der Gaast,J (Hans)-Martin Mb Otten,Heleen M. Ceha,Bengt Glimelius,Cecillia Lagerbäck,Mats Perman,Anders Johnsson,David Borg,Niels H Nielsen,Andrzej Piwowar,Mattias Elmlund,Helene Hörberg,Per Edlund,Bengt Johansson,Petra Flygare,Marie Louise Jespersen +95 more
TL;DR: This investigator-initiated, open-label, randomised phase 3 trial aimed to compare perioperative chemotherapy with preoperative chemotherapy and postoperative chemoradiotherapy in patients with resectable gastric adenocarcinoma.
Journal ArticleDOI
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
Sander Kelderman,Bianca Heemskerk,Harm van Tinteren,Rob R. H. van den Brom,Geke A. P. Hospers,Alfonsus J. M. van den Eertwegh,Ellen Kapiteijn,Jan Willem B. de Groot,Patricia M. M. B. Soetekouw,Rob L. H. Jansen,Edward Fiets,Andrew Furness,Alexandra Renn,Marcin Krzystanek,Zoltan Szallasi,Paul Lorigan,Martin Gore,Ton N. Schumacher,John B. A. G. Haanen,James Larkin,Christian U. Blank +20 more
TL;DR: In both the NL and UK cohorts, long-term benefit of ipilimumab treatment was unlikely for patients with baseline serum LDH greater than twice the upper limit of normal, and baseline serum lactate dehydrogenase was demonstrated to be the strongest predictive factor for OS.